Company news

Eupraxia Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Eupraxia Pharmaceuticals Provides Update for Phase 2 Study in Knee Osteoarthritis for Lead Drug Candidate EP-104IAR

October 11, 2022

Eupraxia Pharmaceuticals Announces Expansion of Intellectual Property For EP-104IAR

September 26, 2022

Eupraxia Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

September 7, 2022

Eupraxia Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 12, 2022

Eupraxia Pharmaceuticals Recognized as Emerging Life Sciences Company of the Year by Life Sciences British Columbia

July 7, 2022

Eupraxia Pharmaceuticals to Present at BIO International Convention

June 8, 2022

Eupraxia Pharmaceuticals Reports First Quarter 2022 Financial Results

May 5, 2022

Eupraxia Pharmaceuticals Completes C$14.7 million Overnight Marketed Offering

April 20, 2022

Eupraxia Pharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

March 29, 2022

Eupraxia Pharmaceuticals to Present at BIO CEO & Investor Conference

February 9, 2022

Eupraxia Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference

January 6, 2022

Eupraxia Pharmaceuticals Inc. Provides Update on its Phase 2 Trial for Osteoarthritis Drug Candidate EP-104IAR

December 2, 2021

Eupraxia Pharmaceuticals Inc. Reports Third Quarter 2021 Financial Results

November 10, 2021

Eupraxia Pharmaceuticals Inc. Announces Research and Development Funding

November 4, 2021

Eupraxia Pharmaceuticals Inc. Provides Update for Phase 2 Osteoarthritis Drug Candidate EP-104IAR

September 16, 2021

Eupraxia Pharmaceuticals Inc. Commences Patient Screening For Its Phase 2 Trial For Osteoarthritis Drug Candidate EP-104IAR

September 14, 2021

Eupraxia Pharmaceuticals Inc. Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

Eupraxia Pharmaceuticals Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results

August 13, 2021

Eupraxia Pharmaceuticals Inc. Announces Authorization of Clinical Trial Application for Phase 2 Trial of EP-104IAR in Osteoarthritis of the Knee

July 19, 2021

Eupraxia Pharmaceuticals Inc. Announces $10 Million Convertible Debt Agreement with Silicon Valley Bank and Conversion of $6.0 Million pre-IPO Debt

June 21, 2021

Eupraxia Pharmaceuticals Inc. Announces Presentation at the Raymond James Human Health Innovations Conference

June 16, 2021

Eupraxia Pharmaceuticals Inc. Provides Corporate Update and Reports First Quarter 2021 Financial Results

May 13, 2021

Eupraxia Pharmaceuticals Inc. Announces Appointment of Bruce Cousins as President & CFO

May 3, 2021

Eupraxia Pharmaceuticals Enters Collaborative Partnership with NBCD for Lead Osteoarthritis (OA) Product Candidate

April 14, 2021

Eupraxia Pharmaceuticals Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference

April 13, 2021

Eupraxia Virtually Opens The Market

March 19, 2021

Eupraxia Pharmaceuticals Inc. Completes Initial Public Offering

March 9, 2021

← Newer news releases

Decks